Sun Industries withdraws application for Doxorubicin SUN
Added: Wednesday 2 November 2011
Sun Pharmaceutical Industries has withdrawn its application for Marketing Authorisiation of Doxorubicin SUN, which was intended to be used in treatment for metastatic breast cancer, advanced ovarian cancer and progressive multiple myeloma, among other uses. Sun withdrew the application because it considered that it would not be possible to answer the objections raised in the time available. The Committee for Medicinal Products for Human Use (CHMP) considered that Sun had not provided enough data to support its application.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: